These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS/MS. Nakajima Y, Ito T, Maeda Y, Ichiki S, Kobayashi S, Ando N, Hussein MH, Kurono Y, Sugiyama N, Togari H. Brain Dev; 2011 Nov; 33(10):816-23. PubMed ID: 21196091 [Abstract] [Full Text] [Related]
14. Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants. Ueshima S, Aiba T, Ishikawa N, Sato T, Kawasaki H, Kurosaki Y, Ohtsuka Y, Sendo T. J Clin Pharm Ther; 2009 Aug; 34(4):415-22. PubMed ID: 19583674 [Abstract] [Full Text] [Related]
15. Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Voudris KA, Attilakos A, Katsarou E, Drakatos A, Dimou S, Mastroyianni S, Skardoutsou A, Prassouli A, Garoufi A. Epilepsy Res; 2006 Aug; 70(2-3):211-7. PubMed ID: 16781120 [Abstract] [Full Text] [Related]
17. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. Hamed SA, Abdella MM. Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440 [Abstract] [Full Text] [Related]